amrubicin amrubicin amrubicin (inn; previously known as sm-5887) is an anthracycline used in the treatment of lung cancer. it is marketed in japan since 2002 by sumitomo under the brand name calsed. amrubicinclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationivatc codel01db10 (who) legal statuslegal status in general: ℞ (prescription only) identifiers iupac name (7s,9s)-9-acetyl-9-amino-7-oxy-6,11-dihydroxy-8,10-dihydro-7h-tetracene-5,12-dione cas number110267-81-7 npubchem cid178149chemspider2299344 yunii93n13lb4z2keggd08854 ychebichebi:135779chemblchembl1186894 ncomptox dashboard (epa)dtxsid30869526 chemical and physical dataformulac25h25no9molar mass483.473 g·mol−13d model (jsmol)interactive image smiles o=c2c1c(o)c5c(c(o)c1c(=o)c3ccccc23)c(c(=o)c)(n)c5o4oc(o)(o)c4 inchi inchi=1s/c25h25no9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33h,6-9,26h2,1h3/t14-,15+,16-,17-,25-/m0/s1 ykey:vjzitpjgsqkzmx-xdprqokasa-n y ny (what is this?) (verify) amrubicin acts by inhibiting topoisomerase ii, and has been compared in clinical trials with topotecan, a topoisomerase i inhibitor. it has also been studied for the treatment of bladder carcinoma and gastric cancer. amrubicin was the first anthracycline derivative created by de novo synthesis and was first published in 1989 by scientists from sumitomo.